NVO - Wegovy's Success - Medicare Contemplates Covering Novo Nordisk's Semaglutide For Heart Health | Benzinga
In a significant development, Medicare may extend coverage for Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (semaglutide) to certain members with a history of heart disease.
The Centers for Medicare and Medicaid Services (CMS) revealed that Medicare Part D drug-benefit plans, overseen by private insurers, could potentially cover anti-obesity medications under specific circumstances.
Earlier this month, the FDA approved Wegovy for expanded use in obesity and cardiovascular disease management.
In August 2023, Novo Nordisk released the headline results from the SELECT cardiovascular outcomes trial, better than the 15-17% expected by investors and analysts.
The trial achieved its primary ...